At a glance
ClinicalIndex Comparison RecordN/ACompleted· 84 enrolled
Drug / intervention
Ferric carboxymaltose (FCM)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Intravenous Ferric Carboxymaltose (FCM) Without Erythropoiesis-stimulating Agents (ESA) in the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy With or Without Radiotherapy
In Brief
A clinical study evaluating Ferric carboxymaltose (FCM) for Anemia and Cancer. Completed, enrolled 84 participants.
Detailed Summary
This study is a nonrandomized, single arm, open-label study stratified by iron-deficiency status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
CollaboratorsHikma Pharmaceuticals LLC
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
Primary CompletionDec 2017
First PostedJan 2020
TodayJul 2026
First PostedJan 29, 2020
Enrollment StartJun 15, 2016
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.4 years ago
Interventions
Ferric carboxymaltose (FCM)drug
intravenous iron formulation